Article
Surveillance of Disease Progression in Metastatic Breast Cancer by Molecular Counting of Circulating Tumor DNA Using Plasma-SeqSensei Breast Cancer in Vitro Diagnostics Assay.
The Journal of molecular diagnostics : JMD - 1 Jan 2025
Martens Geert A, Demol Jan, Dedeurwaerdere Franceska, De Smet Kristof, Wesolowski Janusz, De Smet Dieter
Abstract excerpt
Circulating tumor DNA (ctDNA) quantification surpasses cancer antigen 15 to 3 for metastatic breast cancer surveillance. Clinical translation, however, is limited because of uncertainties about the optimal method and clinically valid ctDNA decision thresholds. Plasma-SeqSensei Breast Cancer IVD kit (PSS) is a novel assay for ctDNA molecular counting, detecting ≥0.06% variant allele fractions in AKT1, ERBB2, ESR1,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.